Oxybutynin – intravesical instillation

Generic name
Oxybutynin – intravesical instillation
Brand name
ATC Code
G04BD04

Oxybutynin – intravesical instillation

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

No information

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Urinary incontinence, overactive bladder syndrome, neurogenic bladder
  • Intravesical
    • 1 year up to 18 years
      • 0.2 - 0.4 mg/kg/day in 2 - 3 doses. Max: 0.9 mg/kg/day. Titrate depending on the effect.

Renal impaiment in children > 3 months

GFR ≥10 ml/min/1.73m2: Dose adjustment not required.

GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects

No information is present at this moment.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

Children can be often more sensitive to parasympatholytic drugs; accurate regulation of the dosage is therefore required.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

UROLOGICALS

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Acidifiers
G04BA01
Drugs for urinary frequency and incontinence
G04BD04
G04BD06
G04BD08
G04BD07
G04BD09
Drugs used in erectile dysfunction
G04BE03
G04BE08
Other urologicals
G04BX16
OTHER UROLOGICALS
G04BX16

References

  1. Verpoorten C, et al, The neurogenic bladder: medical treatment. , Pediatr Nephrol. , 2008, May;23(5), 717-25
  2. Aslan AR, et al, Conservative management in neurogenic bladder dysfunction., Curr Opin Urol., 2002, Nov;12(6), 473-7
  3. Buyse G, et al, Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism, J Urol, 1998, Sep;160(3 Pt 1), 892-6
  4. Ferrara P, et al, Side-effects of oral or intravesical oxybutynin chloride in children with spina bifida, BJU Int, 2001, May;87(7), 674-8
  5. Guerra LA, et al, Intravesical oxybutynin for children with poorly compliant neurogenic bladder: a systematic review, J Urol, 2008, Sep;180(3), 1091-7
  6. Haferkamp A, et al, Dosage escalation of intravesical oxybutynin in the treatment of neurogenic bladder patients, Spinal Cord, 2000, Apr;38(4), 250-4
  7. Kaplinsky R, et al, Expanded followup of intravesical oxybutynin chloride use in children with neurogenic bladder, J Urol, 1996, Aug;156(2 Pt 2), 753-6
  8. Lazarus J., Intravesical oxybutynin in the pediatric neurogenic bladder, Nat Rev Urol, 2009, Dec;6(12), 671-4
  9. Lose G, et al, Intravesical oxybutynin for treating incontinence resulting from an overactive detrusor, BJU Int, 2001, Jun;87(9), 767-73
  10. Verpoorten C, et al, The neurogenic bladder: medical treatment., Pediatr Nephrol., 2008, May;23(5), 717-25

Changes

Therapeutic Drug Monitoring


Overdose